Department of Health and Human Services, through National Institutes of Health, awarded L2 Diagnostics LLC of Woodbridge, CT $599,954 under the STTR program (Phase I), with work starting 2025-09-15 and running to 2027-08-31. It is one of 3 SBIR and STTR awards L2 Diagnostics LLC received in the last two years, $1,223,044 in all. Each figure links to the federal record.
The award
| Recipient | L2 Diagnostics LLC (Woodbridge, CT) |
|---|---|
| Awarding agency | Department of Health and Human Services |
| Awarding office | National Institutes of Health |
| Phase | Phase I |
| Amount obligated | $599,954 |
| Period of performance starts | 2025-09-15 |
| Period of performance ends | 2027-08-31 |
| Award number | R41AI195230 (grant, CFDA 93.855) |
| Assistance listing | 93.855, Allergy and Infectious Diseases Research |
| Place of performance | New Haven, South Central Connecticut County, CT |
| Recipient registry id (UEI) | GKA7VH5LFR25 |
Want the whole picture on L2 Diagnostics LLC?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on L2 Diagnostics LLC: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on L2 Diagnostics LLC covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
32 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What it is for
Pfag, a multivalent peptide vaccine against malaria - abstract pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozo
Funding actions on this award
| Date | Action | Modification | Amount |
|---|---|---|---|
| 2026-08-28 | Continuation | 000 | $300,000 |
| 2025-09-15 | New | 000 | $299,954 |
Pfag, a multivalent peptide vaccine against malaria - abstract pfag is our novel malaria vaccine, composed of short synthetic peptides representing specific immunogenic epitopes of the plasmodium falciparum circumsporozoite (csp) and anopheles gambiae trio (ag trio) proteins. Our prototype pf ag has yielded outstanding early results, including immunogenicity to target antigens and to achieve sterile immunity in an outbred heterogenous CD-1 mouse model. This Phase I feasibility STTR project aims to (i) optimize the prototype pfag vaccine construct and (ii) conduct efficacy testing to confirm the optimal construct design. Our long-term goal is to develop a novel peptide-based vaccine that can be used alone as a multivalent csp/agtrio vaccine or co-administered with existing pre-erythrocytic vaccines such as rts,s and R21 for a more robust immunological initial or boost response. Our target customers include global health and government organizations calling on developing new tools to eradicate malaria. A peptide-based vaccine's safety, production, and cost profile are favorable for addressing the real-world challenges of deploying a vaccine in malaria-endemic, resource-poor countries, where the current malaria eradication approach is limited by efficacy, cost, and logistics issues.
From the federal award record.
Other SBIR and STTR awards to L2 Diagnostics LLC
| Starts | Agency | Program | Amount | Project |
|---|---|---|---|---|
| 2026-09-21 | Department of Health and Human Services | SBIR Phase I | $323,090 | A novel therapeutic, L2ASOCLE, for treating cutaneous lupus erythematosus (cle) - project (record) |
| 2024-12-01 | Department of Health and Human Services | SBIR Phase I | $300,000 | Novel diagnostic biomarkers discovery and validation for malaria SBIR Phase I (record) |
Every other federal award to L2 Diagnostics LLC on record
The federal register lists 29 or more other awards to the same registry id (UEI GKA7VH5LFR25), $35,434,562 in all, from 2 agencies.
| Starts | Agency | Amount | Award |
|---|---|---|---|
| 2025-09-23 | National Institutes of Health | $599,709 | A vaccine targeting mosquito metabolic pathways to eradicate malaria - abstract the world health organization, (R41AI195232) |
| 2025-08-01 | National Institutes of Health | $599,471 | Therapeutic vaccine platform to boost immune responses in tuberculosis (75N93025C00024) |
| 2024-07-17 | National Institutes of Health | $599,938 | The mosquito salivary protein AGBR1 as vaccine candidate against chikungunya - project summary chikungunya is (R41AI186794) |
| 2024-07-08 | National Institutes of Health | $599,866 | A novel therapeutic for lyme arthritis based on a secretory leukocyte protease inhibitor - project summary/abs (R41AI186833) |
| 2024-06-01 | National Institutes of Health | $599,740 | Delivery of a candidate agtriovx malaria vaccine by thermostable microneedle patches - abstract malaria remain (R41AI184218) |
| 2024-05-01 | National Institutes of Health | $597,612 | A multivalent MRNA vaccine to prevent transmission of tick-bornepathogens (R41AI179587) |
| 2021-08-04 | National Institutes of Health | $599,028 | A therapeutic for lyme disease based on peptidoglycan recognition protein 1 - abstract lyme disease, the most (R41AI157014) |
| 2020-06-16 | National Institutes of Health | $593,086 | Vaccination against zika virus infection using mosquito NEST1 protein (R41AI152904) |
| 2019-07-01 | National Institutes of Health | $596,625 | Targets of acquired tick-resistance as anti-tick vaccines (R41AI145778) |
| 2019-01-21 | National Institutes of Health | $2,948,061 | A novel vaccine against mosquito-borne zika virus based on mosquito salivary gland protein AGBR1 - summary arb (R42AI142846) |
| 2019-01-21 | National Institutes of Health | $594,226 | A novel vaccine against mosquito-borne zika virus based on mosquito salivary gland protein AGBR1 (R41AI142846) |
| 2018-06-19 | Department of the Army | $54,980 | Lyme test plates (W911SD18P0204) |
| 2018-01-10 | National Institutes of Health | $2,076,246 | An antigen-detection assay to diagnose babesia microti infection (R44AI136118) |
| 2017-09-19 | National Institutes of Health | $1,996,011 | SBIR Phase II: Topic 338 - predictive biomarkers of adverse reactions to prostrate cancer radiotherapy (HHSN261201700033C) |
| 2016-09-19 | National Institutes of Health | $1,481,590 | Allosteric mif inhibitors for rheumatoid arthritis therapy (R44AR067569) |
| 2015-09-22 | National Institutes of Health | $271,237 | (HHSN261201500043C) |
| 2014-07-01 | National Institutes of Health | $600,000 | RNA detection as an improved diagnostic assay for human leptospirosis (R41AI114064) |
| 2014-07-01 | National Institutes of Health | $599,996 | A multivalent lyme disease vaccine targeting tick-host-pathogen interactions (R41AI112133) |
| 2013-01-01 | National Institutes of Health | $595,406 | A lyme disease vaccine using newly identified in-vivo expressed antigens (R43AI096628) |
| 2012-04-01 | National Institutes of Health | $1,348,103 | Measurement of beta cell death in diabetes (R42DK095639) |
| 2011-11-15 | Department of the Army | $1,146,334 | SBIR phase 1 army 11.2 erms# 11255022, proposal# a112-106-0883 (W81XWH12C0028) |
| 2011-08-15 | National Institutes of Health | $593,976 | A nanoparticle-based vaccine against leishmaniasis (R41AI091234) |
| 2011-08-01 | National Institutes of Health | $1,655,122 | Diagnostic assays for early lyme borreliosis using in-vivo expressed antigens (R44AI096598) |
| 2010-07-15 | National Institutes of Health | $1,343,892 | Bio-monitoring methylene diphenyl diisocyanate (mdi) exposure and body burden (R42ES018021) |
| 2010-03-15 | National Institutes of Health | $2,642,728 | A serologic assay to measure successful lyme borreliosis antibiotic therapy (R44AI085725) |
| 2009-07-01 | National Institutes of Health | $7,021,452 | Broad-spectrum antimicrobials targeting the d-alanine pathway (U01AI082081) |
| 2009-04-01 | National Institutes of Health | $710,274 | New serodiagnostics for isocyanate exposure, a major cause of occupational asthma (R42ES016728) |
| 2008-12-01 | National Institutes of Health | $988,799 | Therapeutic inhibition of mif in rheumatoid arthritis (R44AR056908) |
| 2007-04-01 | National Institutes of Health | $1,381,054 | Egfr peptides as vaccines in anti-tumor immunity (R42CA128165) |
Who runs it, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on L2 Diagnostics LLCLook up L2 Diagnostics LLC first. Finding the company and seeing how much is on record uses no credits.
Look up L2 Diagnostics LLCWhere this comes from
The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs set aside part of federal research budgets for small companies. Agencies award them in phases: Phase I tests whether an idea is feasible, Phase II funds development, and Phase III is follow-on work paid for outside the set-aside. STTR awards also require a research institution as a partner.
Every figure on this page is taken from the award's own federal record, linked beside it, as it stood when the page was built: the recipient, its address, the awarding agency and office, the amount obligated so far, the dates and the description. Phase and program are shown as the award's own description states them. The amount can grow later if the agency adds funding to the same award.